Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 4 Medulloblastoma 2 Recurrence 1 Neoplasms 1 Gliosarcoma 1

Interventions

Cyclophosphamide 9 fludarabine 7 Dexamethasone 7 pomalidomide 6 Rituximab 6 pembrolizumab 5 selinexor 4 obinutuzumab 4 glofitamab 4 Lenalidomide 4 daratumumab 3 belantamab mafodotin 3 Temozolomide 3 Gemcitabine 3 Etoposide 3 Bortezomib 3 zanubrutinib 2 venetoclax 2 tocilizumab 2 fludarabine phosphate 2 enzalutamide 2 cemiplimab 2 carfilzomib 2 abemaciclib 2 PF06821497 2 Mesna 2 Lisaftoclax 2 Injections 2 Immunotherapy, Adoptive 2 Granulocyte Colony-Stimulating Factor 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Lomustine × 30 days × Clear all

NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡